Advertisement

Topics

Kite Pharma submits MAA for axicabtagene ciloleucel in Europe

19:00 EDT 1 Aug 2017 | Pharmaceutical Technology

US-based cell therapy company Kite Pharma has filed a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for axicabtagene ciloleucel.

Original Article: Kite Pharma submits MAA for axicabtagene ciloleucel in Europe

NEXT ARTICLE

More From BioPortfolio on "Kite Pharma submits MAA for axicabtagene ciloleucel in Europe"

Quick Search
Advertisement